X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (842) 842
diabetes mellitus, type 2 - drug therapy (689) 689
male (609) 609
sitagliptin phosphate (584) 584
hypoglycemic agents - therapeutic use (538) 538
sitagliptin (523) 523
female (507) 507
middle aged (455) 455
pyrazines - therapeutic use (436) 436
triazoles - therapeutic use (435) 435
dipeptidyl-peptidase iv inhibitors - therapeutic use (387) 387
type 2 diabetes (383) 383
diabetes (350) 350
endocrinology & metabolism (350) 350
aged (349) 349
sitagliptin phosphate - therapeutic use (291) 291
treatment outcome (270) 270
diabetes mellitus, type 2 - blood (238) 238
animals (227) 227
adult (225) 225
dipeptidyl peptidase-4 inhibitor (209) 209
drug therapy, combination (208) 208
metformin (206) 206
hypoglycemic agents (198) 198
glucose (197) 197
hypoglycemic agents - adverse effects (196) 196
glycemic control (195) 195
pharmacology & pharmacy (191) 191
glucagon-like peptide-1 (189) 189
metformin - therapeutic use (183) 183
blood glucose - metabolism (172) 172
diabetes mellitus (172) 172
double-blind (172) 172
blood glucose - drug effects (165) 165
efficacy (156) 156
hypoglycemic agents - administration & dosage (155) 155
insulin (155) 155
safety (155) 155
care and treatment (153) 153
dipeptidyl-peptidase iv inhibitors - pharmacology (148) 148
glycated hemoglobin a - metabolism (148) 148
pyrazines - pharmacology (146) 146
pyrazines - adverse effects (145) 145
triazoles - pharmacology (144) 144
triazoles - adverse effects (143) 143
double-blind method (139) 139
adamantane - analogs & derivatives (134) 134
hypoglycemic agents - pharmacology (128) 128
dipeptidyl-peptidase iv inhibitors - adverse effects (124) 124
pyrazines - administration & dosage (124) 124
triazoles - administration & dosage (124) 124
analysis (114) 114
diabetes mellitus, type 2 - complications (111) 111
medicine, general & internal (109) 109
adamantane - therapeutic use (108) 108
rats (103) 103
mellitus (101) 101
research (101) 101
diabetes therapy (100) 100
peptides - therapeutic use (98) 98
drug therapy (95) 95
therapy (94) 94
venoms - therapeutic use (94) 94
glycated hemoglobin a - analysis (93) 93
mice (93) 93
internal medicine (92) 92
vildagliptin (92) 92
clinical trials (91) 91
sitagliptin phosphate - adverse effects (90) 90
beta-cell function (89) 89
dosage and administration (88) 88
glucagon (88) 88
hyperglycemia (87) 87
monotherapy (87) 87
dextrose (86) 86
dipeptidyl-peptidase iv inhibitors - administration & dosage (82) 82
insulin resistance (82) 82
sitagliptin phosphate - pharmacology (82) 82
liraglutide (79) 79
hypoglycemia (77) 77
medicine, research & experimental (77) 77
glp-1 (76) 76
risk factors (75) 75
diabetes mellitus, type 2 - metabolism (73) 73
dipeptidyl peptidase-4 inhibitors (73) 73
glycosylated hemoglobin (73) 73
cardiac & cardiovascular systems (72) 72
peptidase (72) 72
sitagliptin phosphate - administration & dosage (72) 72
nitriles - therapeutic use (71) 71
pyrrolidines - therapeutic use (71) 71
type 2 diabetes mellitus (71) 71
dipeptidyl peptidase 4 - metabolism (70) 70
inflammation (70) 70
peptides (70) 70
diabetes mellitus, type 2 - physiopathology (69) 69
dpp-4 inhibitor (68) 68
oxidative stress (68) 68
exenatide (67) 67
risk (67) 67
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (999) 999
German (20) 20
French (11) 11
Japanese (10) 10
Spanish (6) 6
Hungarian (4) 4
Chinese (3) 3
Dutch (3) 3
Portuguese (3) 3
Czech (2) 2
Swedish (2) 2
Italian (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes & metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Diabetic medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
.... Mealtime insulin aspart was used in some regimens. This analysis used the serious adverse events records, which documented the use of ambulance/emergency teams, a hospital/emergency room visit ≤ 24... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TO-TARGET TRIAL | BEGIN | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Complications | Research
Journal Article
Diabetes care, ISSN 0149-5992, 05/2017, Volume 40, Issue 5, pp. 647 - 654
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
The Medical clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article